Study Of Cell Therapeutics' Tosedostat For Elderly Patients With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome Now Enrolling

Patients interested in participating in this study or wanting more information can call Carol Dean (FHCRC) at [phone]. 

About Acute Myelogenous Leukemia (AML)

AML is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells leading to infections and bleeding. AML progresses rapidly and is typically fatal within weeks or months if left untreated. Although a substantial proportion of younger individuals who develop AML can be cured, AML in the elderly typically responds poorly to standard therapy with few complete remissions.

About Tosedostat

Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in phase I-II clinical trials.  CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/. Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of tosedostat include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with tosedostat in particular including, without limitation, the potential failure of tosedostat to prove safe and effective for the treatment of elderly patients with newly-diagnosed AML or high-risk MDS (including when administered in combination with cytarabine or decitabine) as determined by U.S. Food and Drug Administration and/or the European Medicines Agency, the potential failure of combination studies of tosedostat with hypomethylating agents in treating AML and/or MDS, that the phase II study of tosedostat may not achieve its primary and/or secondary objectives, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, determinations by regulatory, patent, and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing, and selling tosedostat, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Clinical Trial Enrollment Contact:

Carol DeanT: [phone]E: [e-mail]

Media Contact:

Dan Eramian T: 206.272.4343C: 206.854.1200E: [e-mail] www.CellTherapeutics.com/press_room

Investors Contact:

Ed BellT: 206.282.7100 Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: [e-mail] www.CellTherapeutics.com/investors

Medical Information Contact:

T: 800.715.0944E: [e-mail]

SOURCE Cell Therapeutics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

« First ‹ Previous 1 2